Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CSF1R |
| Variant | F563_P566del |
| Impact List | deletion |
| Protein Effect | unknown |
| Gene Variant Descriptions | CSF1R F563_P566del results in the deletion of four amino acids in the regulatory juxtamembrane domain of the Csf1r protein from amino acids 563 to 566 (UniProt.org). F563_P566del has been identified in the scientific literature (PMID: 39576953), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Dec 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
CSF1R mutant CSF1R F563_P566del |
| Transcript | NM_001288705.3 |
| gDNA | chr5:g.150061778_150061789del12 |
| cDNA | c.1687_1698del12 |
| Protein | p.F563_P566del |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001349736.2 | chr5:g.150061778_150061789del12 | c.1687_1698del12 | p.F563_P566del | RefSeq | GRCh38/hg38 |
| NM_001375320.1 | chr5:g.150061778_150061789del12 | c.1687_1698del12 | p.F563_P566del | RefSeq | GRCh38/hg38 |
| NM_005211.4 | chr5:g.150061778_150061789del12 | c.1687_1698del12 | p.F563_P566del | RefSeq | GRCh38/hg38 |
| NM_001288705.3 | chr5:g.150061778_150061789del12 | c.1687_1698del12 | p.F563_P566del | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R F563_P566del | Erdheim-Chester disease | predicted - resistant | Pexidartinib | Case Reports/Case Series | Actionable | In a clinical case study, CSF1R F563_P566del was identified at the time of progression, along with loss of the original CSF1R S560_P566del and S938_Y969del mutations, in a patient with Erheim-Chester disease, who originally achieved a partial response with Turalio (pexidartinib) treatment (PMID: 39576953). | 39576953 |